nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Eye disorder—Methylprednisolone—psoriatic arthritis	0.00324	0.00324	CcSEcCtD
Milnacipran—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.00322	0.00322	CcSEcCtD
Milnacipran—Neutropenia—Prednisone—psoriatic arthritis	0.00321	0.00321	CcSEcCtD
Milnacipran—Irritability—Methotrexate—psoriatic arthritis	0.00317	0.00317	CcSEcCtD
Milnacipran—Erectile dysfunction—Prednisone—psoriatic arthritis	0.00316	0.00316	CcSEcCtD
Milnacipran—Angiopathy—Methylprednisolone—psoriatic arthritis	0.00315	0.00315	CcSEcCtD
Milnacipran—Hallucination—Dexamethasone—psoriatic arthritis	0.00314	0.00314	CcSEcCtD
Milnacipran—Hallucination—Betamethasone—psoriatic arthritis	0.00314	0.00314	CcSEcCtD
Milnacipran—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.00313	0.00313	CcSEcCtD
Milnacipran—Weight decreased—Prednisone—psoriatic arthritis	0.00311	0.00311	CcSEcCtD
Milnacipran—Vision blurred—Prednisolone—psoriatic arthritis	0.0031	0.0031	CcSEcCtD
Milnacipran—Liver function test abnormal—Methotrexate—psoriatic arthritis	0.00307	0.00307	CcSEcCtD
Milnacipran—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00304	0.00304	CcSEcCtD
Milnacipran—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00302	0.00302	CcSEcCtD
Milnacipran—Breast disorder—Methotrexate—psoriatic arthritis	0.003	0.003	CcSEcCtD
Milnacipran—Dysgeusia—Triamcinolone—psoriatic arthritis	0.00296	0.00296	CcSEcCtD
Milnacipran—Syncope—Prednisolone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Milnacipran—Eye disorder—Dexamethasone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Milnacipran—Eye disorder—Betamethasone—psoriatic arthritis	0.00295	0.00295	CcSEcCtD
Milnacipran—Loss of consciousness—Prednisolone—psoriatic arthritis	0.00289	0.00289	CcSEcCtD
Milnacipran—Angiopathy—Dexamethasone—psoriatic arthritis	0.00286	0.00286	CcSEcCtD
Milnacipran—Angiopathy—Betamethasone—psoriatic arthritis	0.00286	0.00286	CcSEcCtD
Milnacipran—Convulsion—Prednisolone—psoriatic arthritis	0.00285	0.00285	CcSEcCtD
Milnacipran—Hypertension—Prednisolone—psoriatic arthritis	0.00284	0.00284	CcSEcCtD
Milnacipran—Hallucination—Prednisone—psoriatic arthritis	0.00273	0.00273	CcSEcCtD
Milnacipran—Syncope—Triamcinolone—psoriatic arthritis	0.00272	0.00272	CcSEcCtD
Milnacipran—Syncope—Methylprednisolone—psoriatic arthritis	0.00271	0.00271	CcSEcCtD
Milnacipran—Connective tissue disorder—Prednisone—psoriatic arthritis	0.0027	0.0027	CcSEcCtD
Milnacipran—Neutropenia—Methotrexate—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Milnacipran—Dysuria—Methotrexate—psoriatic arthritis	0.00268	0.00268	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.00267	0.00267	CcSEcCtD
Milnacipran—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Milnacipran—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.00266	0.00266	CcSEcCtD
Milnacipran—Shock—Prednisolone—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Milnacipran—Erectile dysfunction—Methotrexate—psoriatic arthritis	0.00264	0.00264	CcSEcCtD
Milnacipran—Convulsion—Triamcinolone—psoriatic arthritis	0.00262	0.00262	CcSEcCtD
Milnacipran—Tachycardia—Prednisolone—psoriatic arthritis	0.00262	0.00262	CcSEcCtD
Milnacipran—Convulsion—Methylprednisolone—psoriatic arthritis	0.00262	0.00262	CcSEcCtD
Milnacipran—Hypertension—Triamcinolone—psoriatic arthritis	0.00261	0.00261	CcSEcCtD
Milnacipran—Hypertension—Methylprednisolone—psoriatic arthritis	0.00261	0.00261	CcSEcCtD
Milnacipran—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.0026	0.0026	CcSEcCtD
Milnacipran—Eye disorder—Prednisone—psoriatic arthritis	0.00257	0.00257	CcSEcCtD
Milnacipran—Anxiety—Methylprednisolone—psoriatic arthritis	0.00256	0.00256	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00255	0.00255	CcSEcCtD
Milnacipran—Flushing—Prednisone—psoriatic arthritis	0.00255	0.00255	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.00254	0.00254	CcSEcCtD
Milnacipran—Dry mouth—Triamcinolone—psoriatic arthritis	0.00252	0.00252	CcSEcCtD
Milnacipran—Angiopathy—Prednisone—psoriatic arthritis	0.00249	0.00249	CcSEcCtD
Milnacipran—Syncope—Betamethasone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Milnacipran—Syncope—Dexamethasone—psoriatic arthritis	0.00246	0.00246	CcSEcCtD
Milnacipran—Infection—Triamcinolone—psoriatic arthritis	0.00245	0.00245	CcSEcCtD
Milnacipran—Infection—Methylprednisolone—psoriatic arthritis	0.00245	0.00245	CcSEcCtD
Milnacipran—Haematuria—Methotrexate—psoriatic arthritis	0.00244	0.00244	CcSEcCtD
Milnacipran—Shock—Triamcinolone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Milnacipran—Insomnia—Prednisolone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Milnacipran—Shock—Methylprednisolone—psoriatic arthritis	0.00243	0.00243	CcSEcCtD
Milnacipran—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.00242	0.00242	CcSEcCtD
Milnacipran—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00242	0.00242	CcSEcCtD
Milnacipran—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Milnacipran—Loss of consciousness—Betamethasone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Milnacipran—Paraesthesia—Prednisolone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Milnacipran—Tachycardia—Triamcinolone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Milnacipran—Mental disorder—Prednisone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Milnacipran—Tachycardia—Methylprednisolone—psoriatic arthritis	0.00241	0.00241	CcSEcCtD
Milnacipran—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00239	0.00239	CcSEcCtD
Milnacipran—Malnutrition—Prednisone—psoriatic arthritis	0.00239	0.00239	CcSEcCtD
Milnacipran—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00239	0.00239	CcSEcCtD
Milnacipran—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Milnacipran—Convulsion—Dexamethasone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Milnacipran—Convulsion—Betamethasone—psoriatic arthritis	0.00238	0.00238	CcSEcCtD
Milnacipran—Hypertension—Betamethasone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Milnacipran—Hypertension—Dexamethasone—psoriatic arthritis	0.00237	0.00237	CcSEcCtD
Milnacipran—Anxiety—Dexamethasone—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Milnacipran—Anxiety—Betamethasone—psoriatic arthritis	0.00233	0.00233	CcSEcCtD
Milnacipran—Hypotension—Methylprednisolone—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Milnacipran—Hepatitis—Methotrexate—psoriatic arthritis	0.0023	0.0023	CcSEcCtD
Milnacipran—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00227	0.00227	CcSEcCtD
Milnacipran—Vision blurred—Prednisone—psoriatic arthritis	0.00225	0.00225	CcSEcCtD
Milnacipran—Urethral disorder—Methotrexate—psoriatic arthritis	0.00225	0.00225	CcSEcCtD
Milnacipran—Insomnia—Triamcinolone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Milnacipran—Insomnia—Methylprednisolone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Milnacipran—Infection—Betamethasone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Milnacipran—Infection—Dexamethasone—psoriatic arthritis	0.00223	0.00223	CcSEcCtD
Milnacipran—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00222	0.00222	CcSEcCtD
Milnacipran—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Milnacipran—Shock—Dexamethasone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Milnacipran—Shock—Betamethasone—psoriatic arthritis	0.00221	0.00221	CcSEcCtD
Milnacipran—Dyspnoea—Triamcinolone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Milnacipran—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Milnacipran—Nervous system disorder—Betamethasone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Milnacipran—Agitation—Prednisone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Milnacipran—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Milnacipran—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.0022	0.0022	CcSEcCtD
Milnacipran—Tachycardia—Dexamethasone—psoriatic arthritis	0.00219	0.00219	CcSEcCtD
Milnacipran—Tachycardia—Betamethasone—psoriatic arthritis	0.00219	0.00219	CcSEcCtD
Milnacipran—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Milnacipran—Erythema multiforme—Methotrexate—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Milnacipran—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Milnacipran—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Milnacipran—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Milnacipran—Eye disorder—Methotrexate—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Milnacipran—Syncope—Prednisone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Milnacipran—Anorexia—Betamethasone—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Milnacipran—Anorexia—Dexamethasone—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Milnacipran—Urticaria—Prednisolone—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Milnacipran—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Milnacipran—Fatigue—Triamcinolone—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Milnacipran—Fatigue—Methylprednisolone—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Milnacipran—Loss of consciousness—Prednisone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Milnacipran—Hypotension—Dexamethasone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Milnacipran—Hypotension—Betamethasone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Milnacipran—Angiopathy—Methotrexate—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Milnacipran—Convulsion—Prednisone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Milnacipran—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Milnacipran—Hypertension—Prednisone—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Milnacipran—Chills—Methotrexate—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Milnacipran—Anxiety—Prednisone—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Milnacipran—Insomnia—Dexamethasone—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Milnacipran—Insomnia—Betamethasone—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Milnacipran—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Milnacipran—Paraesthesia—Betamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Milnacipran—Mental disorder—Methotrexate—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Milnacipran—Malnutrition—Methotrexate—psoriatic arthritis	0.002	0.002	CcSEcCtD
Milnacipran—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Milnacipran—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Milnacipran—Dyspepsia—Betamethasone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Milnacipran—Urticaria—Triamcinolone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Milnacipran—Urticaria—Methylprednisolone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Milnacipran—Dysgeusia—Methotrexate—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Milnacipran—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Milnacipran—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Milnacipran—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Milnacipran—Decreased appetite—Betamethasone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Milnacipran—Infection—Prednisone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Milnacipran—Fatigue—Dexamethasone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Milnacipran—Fatigue—Betamethasone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Milnacipran—Shock—Prednisone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Milnacipran—Nervous system disorder—Prednisone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Milnacipran—Tachycardia—Prednisone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Milnacipran—Skin disorder—Prednisone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Milnacipran—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Milnacipran—Vision blurred—Methotrexate—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Milnacipran—Anorexia—Prednisone—psoriatic arthritis	0.00186	0.00186	CcSEcCtD
Milnacipran—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Milnacipran—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00183	0.00183	CcSEcCtD
Milnacipran—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Milnacipran—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Milnacipran—Leukopenia—Methotrexate—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Milnacipran—Urticaria—Dexamethasone—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Milnacipran—Urticaria—Betamethasone—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Milnacipran—Dizziness—Prednisolone—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Milnacipran—Asthenia—Triamcinolone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Body temperature increased—Dexamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Body temperature increased—Betamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Abdominal pain—Betamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Asthenia—Methylprednisolone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Insomnia—Prednisone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Milnacipran—Paraesthesia—Prednisone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Milnacipran—Pruritus—Triamcinolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Milnacipran—Pruritus—Methylprednisolone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Milnacipran—Convulsion—Methotrexate—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Milnacipran—Dyspepsia—Prednisone—psoriatic arthritis	0.00172	0.00172	CcSEcCtD
Milnacipran—Chest pain—Methotrexate—psoriatic arthritis	0.0017	0.0017	CcSEcCtD
Milnacipran—Decreased appetite—Prednisone—psoriatic arthritis	0.0017	0.0017	CcSEcCtD
Milnacipran—Rash—Prednisolone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Milnacipran—Dermatitis—Prednisolone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Milnacipran—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Milnacipran—Fatigue—Prednisone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Milnacipran—Headache—Prednisolone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Milnacipran—Constipation—Prednisone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Milnacipran—Dizziness—Triamcinolone—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Milnacipran—Dizziness—Methylprednisolone—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Milnacipran—Infection—Methotrexate—psoriatic arthritis	0.00162	0.00162	CcSEcCtD
Milnacipran—Asthenia—Betamethasone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Milnacipran—Asthenia—Dexamethasone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Milnacipran—Nervous system disorder—Methotrexate—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Milnacipran—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Milnacipran—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Milnacipran—Nausea—Prednisolone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Milnacipran—Pruritus—Betamethasone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Milnacipran—Pruritus—Dexamethasone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Milnacipran—Skin disorder—Methotrexate—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Milnacipran—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Milnacipran—Vomiting—Triamcinolone—psoriatic arthritis	0.00157	0.00157	CcSEcCtD
Milnacipran—Vomiting—Methylprednisolone—psoriatic arthritis	0.00157	0.00157	CcSEcCtD
Milnacipran—Rash—Triamcinolone—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Milnacipran—Dermatitis—Triamcinolone—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Milnacipran—Anorexia—Methotrexate—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Milnacipran—Rash—Methylprednisolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Milnacipran—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Milnacipran—Urticaria—Prednisone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Milnacipran—Headache—Triamcinolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Milnacipran—Headache—Methylprednisolone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Milnacipran—Body temperature increased—Prednisone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Milnacipran—Abdominal pain—Prednisone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Milnacipran—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Milnacipran—Diarrhoea—Betamethasone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Milnacipran—Hypotension—Methotrexate—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Milnacipran—Dizziness—Dexamethasone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Milnacipran—Dizziness—Betamethasone—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Milnacipran—Insomnia—Methotrexate—psoriatic arthritis	0.00148	0.00148	CcSEcCtD
Milnacipran—Nausea—Triamcinolone—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Milnacipran—Paraesthesia—Methotrexate—psoriatic arthritis	0.00147	0.00147	CcSEcCtD
Milnacipran—Nausea—Methylprednisolone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Milnacipran—Dyspnoea—Methotrexate—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Milnacipran—Somnolence—Methotrexate—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Milnacipran—Hypersensitivity—Prednisone—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Milnacipran—Dyspepsia—Methotrexate—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Milnacipran—Vomiting—Betamethasone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Milnacipran—Vomiting—Dexamethasone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Milnacipran—Decreased appetite—Methotrexate—psoriatic arthritis	0.00142	0.00142	CcSEcCtD
Milnacipran—Rash—Betamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Milnacipran—Rash—Dexamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Milnacipran—Dermatitis—Dexamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Milnacipran—Dermatitis—Betamethasone—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Milnacipran—Fatigue—Methotrexate—psoriatic arthritis	0.00141	0.00141	CcSEcCtD
Milnacipran—Headache—Betamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Milnacipran—Headache—Dexamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Milnacipran—Asthenia—Prednisone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Milnacipran—Pruritus—Prednisone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Milnacipran—Diarrhoea—Prednisone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Milnacipran—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Milnacipran—Nausea—Betamethasone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Milnacipran—Nausea—Dexamethasone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Milnacipran—Urticaria—Methotrexate—psoriatic arthritis	0.0013	0.0013	CcSEcCtD
Milnacipran—Dizziness—Prednisone—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Milnacipran—Abdominal pain—Methotrexate—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Milnacipran—Body temperature increased—Methotrexate—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Milnacipran—Vomiting—Prednisone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Milnacipran—Rash—Prednisone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Milnacipran—Dermatitis—Prednisone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Milnacipran—Headache—Prednisone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Milnacipran—Hypersensitivity—Methotrexate—psoriatic arthritis	0.0012	0.0012	CcSEcCtD
Milnacipran—Asthenia—Methotrexate—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Milnacipran—Nausea—Prednisone—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Milnacipran—Pruritus—Methotrexate—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Milnacipran—Diarrhoea—Methotrexate—psoriatic arthritis	0.00112	0.00112	CcSEcCtD
Milnacipran—Dizziness—Methotrexate—psoriatic arthritis	0.00108	0.00108	CcSEcCtD
Milnacipran—Vomiting—Methotrexate—psoriatic arthritis	0.00104	0.00104	CcSEcCtD
Milnacipran—Rash—Methotrexate—psoriatic arthritis	0.00103	0.00103	CcSEcCtD
Milnacipran—Dermatitis—Methotrexate—psoriatic arthritis	0.00103	0.00103	CcSEcCtD
Milnacipran—Headache—Methotrexate—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Milnacipran—Nausea—Methotrexate—psoriatic arthritis	0.000969	0.000969	CcSEcCtD
